ERBB2 and breast carcinoma: Despite this, an interesting finding in the present study was that all HER2-overexpressing CMCs expressed BCRP, which was consistent with studies regarding breast cancer; it could be related to unfavorable prognostic factors and suggests to administer the therapeutic protocol targeting HER2 avoiding conventional chemotherapeutic drugs that are BCRP substrates [47,48].